RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Denali Therapeutics Stock

Denali Therapeutics ROA 2025

Denali Therapeutics ROA

-0.31

Ticker

DNLI

ISIN

US24823R1059

WKN

A2H9G8

In 2025, Denali Therapeutics's return on assets (ROA) was -0.31, a 144.46% increase from the -0.13 ROA in the previous year.

Denali Therapeutics Aktienanalyse

What does Denali Therapeutics do?

Denali Therapeutics Inc is a biotechnology company specializing in the research and development of therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2015 by four former employees of Genentech, with the goal of finding innovative treatments for serious neurological conditions. Denali Therapeutics' business model is based on a patented platform technology that allows the company to target and deliver its drugs precisely to the brain of patients. The company utilizes "liposomes," microscopic bubbles of fat that are loaded with the drug and then transported to the brain through the bloodstream. Denali Therapeutics is divided into three divisions: development platform, therapy development, and diagnosis development. The development platform is the core business of Denali Therapeutics. Here, the company continues to develop its liposome technology to be used for various neurological diseases. The therapy development focuses on developing targeted drugs for specific neurodegenerative diseases. Denali Therapeutics collaborates closely with neurologists and other experts to develop the best possible therapies for patients. The diagnosis development aims to detect early symptoms of neurodegenerative diseases, enabling early diagnosis and treatment. Denali Therapeutics is primarily working on the development of testing methods that will allow for early detection of Alzheimer's and Parkinson's. Currently, Denali Therapeutics has several promising drugs in its pipeline. One of the most important projects is a drug for Alzheimer's disease, which is currently being tested in clinical trials. The drug targets the accumulation of beta-amyloid, which is responsible for the progression of the disease. Another promising project is a drug for Parkinson's, which is also being tested in clinical trials. The drug targets the accumulation of alpha-synuclein, a protein implicated in the development of Parkinson's. Denali Therapeutics aims to develop new therapies for neurodegenerative diseases to improve the lives of patients. The company is committed to answering the many unanswered medical questions in the field of neurology and making a contribution to overcoming these serious diseases. Denali Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Denali Therapeutics's Return on Assets (ROA)

Denali Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Denali Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Denali Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Denali Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Denali Therapeutics stock

What is the Return on Assets (ROA) of Denali Therapeutics this year?

The Return on Assets (ROA) of Denali Therapeutics is -0.31 undefined this year.

What was the ROA of Denali Therapeutics compared to the previous year?

The ROA of Denali Therapeutics has increased by 144.46% compared to the previous year.

What consequences do high ROA have for investors of Denali Therapeutics?

A high ROA is advantageous for investors of Denali Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Denali Therapeutics?

A low ROA can be unfavorable for investors of Denali Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Denali Therapeutics affect the company?

An increase in ROA of Denali Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Denali Therapeutics impact the company?

A reduction in the ROA of Denali Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Denali Therapeutics?

Some factors that can influence the ROA of Denali Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Denali Therapeutics important for investors?

The ROA of Denali Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Denali Therapeutics take to improve ROA?

To improve ROA, Denali Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Denali Therapeutics pay?

Over the past 12 months, Denali Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Denali Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Denali Therapeutics?

The current dividend yield of Denali Therapeutics is .

When does Denali Therapeutics pay dividends?

Denali Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Denali Therapeutics?

Denali Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Denali Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Denali Therapeutics located?

Denali Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Denali Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Denali Therapeutics from 4/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/17/2025.

When did Denali Therapeutics pay the last dividend?

The last dividend was paid out on 4/17/2025.

What was the dividend of Denali Therapeutics in the year 2024?

In the year 2024, Denali Therapeutics distributed 0 USD as dividends.

In which currency does Denali Therapeutics pay out the dividend?

The dividends of Denali Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Denali Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Denali Therapeutics

Our stock analysis for Denali Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Denali Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.